Stephen Hoge sold $2.7M of MRNA
President at Moderna, Inc.. 53,336 shares at an average of $51.37, traded Jun 15, 2026, filed Jun 17, 2026.
Score components
- +20RolePresident
- +25Trade size$2.7M at market
- 0Share of holdings soldSold 3.5% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001682852-26-000121, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 15, 2026 | MOption exercise Common Stock10b5-1 | +37,226 | $19.15 | $713k | 1,521,074 | Jun 17, 2026 |
| Jun 15, 2026 | MOption exercise Common Stock10b5-1 | +16,110 | $19.15 | $309k | 1,537,184 | Jun 17, 2026 |
| Jun 15, 2026 | SOpen-market sale Common Stock10b5-1 | -53,336 | $51.37 | $2.7M | 1,483,848 | Jun 17, 2026 |
| Jun 15, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -37,226 | $0.00 | $0 | 37,226 | Jun 17, 2026 |
| Jun 15, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -16,110 | $0.00 | $0 | 16,110 | Jun 17, 2026 |
Related signals
Other insiders at Moderna, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 25Weak | Moderna, Inc. | Stephen Hoge President | $12M 80,575 shares | -5% | |
| 37Weak | Moderna, Inc. | James M Mock Chief Financial Officer | $4.7M 34,836 shares | -37% | |
| 13Weak | Moderna, Inc. | Shannon Thyme Klinger Chief Legal Officer | $486k 3,471 shares | -4% | |
| 15Weak | Moderna, Inc. | Stephane Bancel Chief Executive Officer | $29M 499,246 shares | -7% | |
| 10Weak | Moderna, Inc. | Stephen Hoge President | $3.6M 53,336 shares | -3% | |
| 6Weak | Moderna, Inc. | Shannon Thyme Klinger Chief Legal Officer | $174k 3,471 shares | -5% | |
| 52Moderate | Moderna, Inc. | Noubar Afeyan director | $434k 9,263 shares | -70% | |
| 25Weak | Moderna, Inc. | Stephen Hoge President | $2.6M 53,336 shares | -3% | |
| 11Weak | Moderna, Inc. | Abbas Hussain director | $265k 5,682 shares | -32% | |
| 14Weak | Moderna, Inc. | Shannon Thyme Klinger Chief Legal Officer | $726k 13,885 shares | -19% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.